AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
AnaptysBio's operating cash flow for the twelve months ending Jun 30, 2026 was $18.08M. For fiscal 2025 it was $19.70M. The highest annual figure on record is $19.70M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.70M | – |
| FY2024 | Dec 31, 2024 | -$135.34M | – |
| FY2023 | Dec 31, 2023 | -$120.80M | – |
| FY2022 | Dec 31, 2022 | -$73.59M | – |
| FY2021 | Dec 31, 2021 | -$45.92M | – |
| FY2020 | Dec 31, 2020 | -$14.16M | – |
| FY2019 | Dec 31, 2019 | -$69.52M | – |
| FY2018 | Dec 31, 2018 | -$48.51M | – |
| FY2017 | Dec 31, 2017 | -$19.44M | – |
| FY2016 | Dec 31, 2016 | -$9.03M | – |
| FY2015 | Dec 31, 2015 | -$9.69M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.92M | – |
| Q4 FY2025 | Dec 31, 2025 | $98.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$66.67M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$34.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.15M | -351.8% |
| Q1 FY2022 | Mar 31, 2022 | -$21.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.30M | -167.3% |
| Q3 FY2021 | Sep 30, 2021 | -$7.01M | – |
| Q2 FY2021 | Jun 30, 2021 | $9.59M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $37.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.29M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.86M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.48M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.81M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.10M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.07M | – |
See a number that looks wrong?